These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Serum prolactin level in patients with multiple sclerosis: a case control study. Harirchian MH; Sahraian MA; Shirani A Med Sci Monit; 2006 Apr; 12(4):CR177-80. PubMed ID: 16572053 [TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis and hyperprolactinemia: a case-control study. Etemadifar M; Najafi MA; Najafi MR; Alavi A; Nasr Z; Farokhi M; Rezaei A Acta Neurol Belg; 2015 Sep; 115(3):253-7. PubMed ID: 25501283 [TBL] [Abstract][Full Text] [Related]
4. [Pathogenetic role of prolactinemia in multiple sclerosis]. Golovkin VI; Mikhaĭlenko AA; Rakov AL Sov Med; 1991; (10):15-7. PubMed ID: 1801224 [TBL] [Abstract][Full Text] [Related]
5. Hyperprolactinemia in multiple sclerosis. Kira J; Harada M; Yamaguchi Y; Shida N; Goto I J Neurol Sci; 1991 Mar; 102(1):61-6. PubMed ID: 1906932 [TBL] [Abstract][Full Text] [Related]
6. Hyperprolactinemia in optico-spinal multiple sclerosis. Yamasaki K; Horiuchi I; Minohara M; Osoegawa M; Kawano Y; Ohyagi Y; Yamada T; Kira J Intern Med; 2000 Apr; 39(4):296-9. PubMed ID: 10801143 [TBL] [Abstract][Full Text] [Related]
7. Serum prolactin level in patients with relapsing-remitting multiple sclerosis during relapse. Moshirzadeh S; Ghareghozli K; Harandi AA; Pakdaman H J Clin Neurosci; 2012 Apr; 19(4):622-3. PubMed ID: 22341909 [TBL] [Abstract][Full Text] [Related]
8. Resolution of inflammation during multiple sclerosis. Ruiz F; Vigne S; Pot C Semin Immunopathol; 2019 Nov; 41(6):711-726. PubMed ID: 31732775 [TBL] [Abstract][Full Text] [Related]
9. Environmental triggers in multiple sclerosis. Fact or fallacy? Morrison W; Nelson J Axone; 1994 Sep; 16(1):23-6. PubMed ID: 7880765 [TBL] [Abstract][Full Text] [Related]
10. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908 [TBL] [Abstract][Full Text] [Related]
11. Treating prolactinoma can prevent autoimmune diseases. Watad A; Versini M; Jeandel PY; Amital H; Shoenfeld Y Cell Immunol; 2015 Apr; 294(2):84-6. PubMed ID: 25468803 [TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis: immune mechanism and update on current therapies. Bansil S; Cook SD; Rohowsky-Kochan C Ann Neurol; 1995 May; 37 Suppl 1():S87-101. PubMed ID: 8968220 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS. Zivadinov R; Munschauer FE; Ramanathan M; Benedict RH; Weinstock-Guttman B Drugs Today (Barc); 2008 Aug; 44(8):601-13. PubMed ID: 18846271 [TBL] [Abstract][Full Text] [Related]
14. Serum Prolactin Levels in Multiple Sclerosis, Neuromyelitis Optica, and Clinically Isolated Syndrome Patients. Türkoğlu R; Giriş M; Gencer M; Akcan U; Örçen A Noro Psikiyatr Ars; 2016 Dec; 53(4):353-356. PubMed ID: 28360812 [TBL] [Abstract][Full Text] [Related]